EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Evi B Struble iD, Jonathan M O Rawson, Tzanko Stantchev, Dorothy Scott, Marjorie A Shapiro

Pharmaceutics · 19.05.2023 · 15 (5) · 1538

DOI: 10.3390/pharmaceutics15051538 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 19.05.2023. Verfasst von Evi B Struble und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Resear…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 259 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.

Schlagwörter

Stichwörter der Autor:innen

antibody combination therapyantibody potencyantiviral antibodiesantiviral therapypotency assays

Autor:innen und Institutionen

  • Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 2099…
  • Division of Antivirals, Office of Infectious Diseases, Office of New Drugs, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD 20993, USA.
  • Division of Biotechnology Review and Research 1, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD…

ORCID-Profile: Evi B Struble

Zitieren

APA

Struble, E. B., Rawson, J. M. O., Stantchev, T., Scott, D., & Shapiro, M. A. (2023). Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies. Pharmaceutics, 15(5), 1538. https://doi.org/10.3390/pharmaceutics15051538

Vancouver

Struble EB, Rawson JMO, Stantchev T, Scott D, Shapiro MA. Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies. Pharmaceutics. 2023;15(5):1538. doi:10.3390/pharmaceutics15051538

BibTeX
@article{Struble2023,
  author = {Struble, Evi B and Rawson, Jonathan M O and Stantchev, Tzanko and Scott, Dorothy and Shapiro, Marjorie A},
  title = {Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1538},
  doi = {10.3390/pharmaceutics15051538}
}
Kostenlos starten →